Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...
Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.
As Ozempic use rises, society’s obsession with thinness is erasing body positivity and real, authentic bodies.
Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback